quinoid dihydropteridine reductase
Última atualização 18 de ago de 2020
Atende aos diretrizes editoriais
- BaixarBaixar
- Compartilhar
- Language
- Discussão
- Ask Patient
- Versão em Áudio
- Adicionar às fontes preferidas no Google
A QDPR gene provides instructions for making an enzyme called quinoid dihydropteridine reductase. This enzyme helps carry out one step in the chemical pathway that recycles a molecule called tetrahydrobiopterin (BH4).
Escolhas de vídeos para GenesBiblioteca de vídeos
Normal function
A QDPR gene provides instructions for making an enzyme called quinoid dihydropteridine reductase. This enzyme helps carry out one step in the chemical pathway that recycles a molecule called tetrahydrobiopterin (BH4).
Tetrahydrobiopterin plays a critical role in processing several protein building blocks (amino acids) in the body. For example, it works with the enzyme phenylalanine hydroxylase to convert an amino acid called phenylalanine into another amino acid, tyrosine. Tetrahydrobiopterin is also involved in reactions that produce chemicals called neurotransmitters, which transmit signals between nerve cells in the brain. Because it helps enzymes carry out chemical reactions, tetrahydrobiopterin is known as a cofactor.
When tetrahydrobiopterin interacts with enzymes during chemical reactions, the cofactor is altered and must be recycled to a usable form. Quinoid dihydropteridine reductase is one of two enzymes that help recycle tetrahydrobiopterin in the body.
Conditions referring to this gene or chromosome
Other names
DHPR
DHPR_HUMAN
Dihydropteridine reductase
PKU2
SDR33C1
Related patient information and medicines

Patient information leaflet
Problemas de próstata
This leaflet will... There are various treatments for the symptoms of BPH, including drugs such as alfuzosin/doxazosin (alpha-blockers), dutasteride/finasteride (5-alpha reductase inhibitors), oxybutinin/tolterodine/fesoterodine/darifenacin/solifenacin/trospium (antimuscarinics), mirabegron (for overactive bladder) and desmopressin (for frequent.

Patient information leaflet
Próstata aumentada
The prostate gland commonly becomes larger in older men. Women do not have a prostate gland. There are two groups of medicines that may help: Alpha-blockers. Inibidores da 5-alfa redutase. Medicines do not cure t... These work by blocking the conversion of the hormone testosterone to dihydrotestosterone in the prostate. They do this by blocking a.

Patient information leaflet
Sangue no sêmen
Hematospérmia means there is blood in the semen. Usually there are no other symptoms such as pain. The haematospermia itself does not need any treatment. Medicines If you have persistent haematospermia without an identified cause then a type of medicine called a 5-alpha reductase inhibitor tais como finasteride Finasteride for prostate gland.

Medicine leaflet
Comprimidos de Pravastatina
Over time, these patches can make a blood vessel narrower and this is called... The narrowing reduces the blood flow through the artery and increases the risk of a number of heart and blood vessel diseases, such as heart attack and stroke. Pravastatin belongs to a group of medicines known as estatinas (or HMG-CoA reductase inhibitors). It reduces.

Medicine leaflet
Finasterida para aumento da glândula prostática
Finasteride is for men only. It must not be taken by women, children... Your symptoms may start to improve within a few weeks, although it can take up to six months for you to notice the full benefit. About finasterida Tipo de medicamento 5-alpha reductase inhibitor Used for Enlargement of the prostate gland in men Also called Proscar® Available as.

Medicine leaflet
Dutasterida para aumento da glândula prostática
Dutasteride is for men only. Your symptoms may start to improve within a few wee... About dutasterida Tipo de medicamento 5-alpha reductase inhibitor Used for Enlargement of the prostate gland in men Also called Avodart®; Combination brands: Combodart®; Dutrozen® (dutasteride with tamsulosin Tamsulosin for prostate gland enlargement ) Available as.
Leitura adicional e referências
- quinoid dihydropteridine reductase; MedlinePlus, National Library of Medicine.
- Dianzani I, de Sanctis L, Smooker PM, Gough TJ, Alliaudi C, Brusco A, Spada M, Blau N, Dobos M, Zhang HP, Yang N, Ponzone A, Armarego WL, Cotton RG. Dihydropteridine reductase deficiency: physical structure of the QDPR gene, identification of two new mutations and genotype-phenotype correlations. Hum Mutat. 1998;12(4):267-73. doi: 10.1002/(SICI)1098-1004(1998)12:43.0.CO;2-C.
- Longo N. Disorders of biopterin metabolism. J Inherit Metab Dis. 2009 Jun;32(3):333-42. doi: 10.1007/s10545-009-1067-2. Epub 2009 Feb 9.
- Ponzone A, Spada M, Ferraris S, Dianzani I, de Sanctis L. Dihydropteridine reductase deficiency in man: from biology to treatment. Med Res Rev. 2004 Mar;24(2):127-50. doi: 10.1002/med.10055.
- Romstad A, Kalkanoglu HS, Coskun T, Demirkol M, Tokatli A, Dursun A, Baykal T, Ozalp I, Guldberg P, Guttler F. Molecular analysis of 16 Turkish families with DHPR deficiency using denaturing gradient gel electrophoresis (DGGE). Hum Genet. 2000 Dec;107(6):546-53. doi: 10.1007/s004390000407.
- Shintaku H. Disorders of tetrahydrobiopterin metabolism and their treatment. Curr Drug Metab. 2002 Apr;3(2):123-31. doi: 10.2174/1389200024605145.
- Thony B, Auerbach G, Blau N. Tetrahydrobiopterin biosynthesis, regeneration and functions. Biochem J. 2000 Apr 1;347 Pt 1(Pt 1):1-16.
- Thony B, Blau N. Mutations in the BH4-metabolizing genes GTP cyclohydrolase I, 6-pyruvoyl-tetrahydropterin synthase, sepiapterin reductase, carbinolamine-4a-dehydratase, and dihydropteridine reductase. Hum Mutat. 2006 Sep;27(9):870-8. doi: 10.1002/humu.20366.
Compartilhe seus pensamentos ou experiências com outros em nosso comunidades de pacientes.
Inscreva-se no boletim informativo do Patient
Sua dose semanal de conselhos de saúde claros e confiáveis - escritos para ajudá-lo a se sentir informado, confiante e no controle.
Ao se inscrever, você aceita nossos Política de Privacidade. Você pode cancelar a inscrição a qualquer momento. Nunca vendemos seus dados.

